Wang DR. Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis. World J Clin Cases 2023; 11(23): 5447-5454 [PMID: 37637703 DOI: 10.12998/wjcc.v11.i23.5447]
Corresponding Author of This Article
Ding-Ran Wang, PhD, Attending Doctor, Department of Obstetrics and Gynaecology, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. ydausidb@163.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2023; 11(23): 5447-5454 Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5447
Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
Ding-Ran Wang
Ding-Ran Wang, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing 100191, China
Author contributions: Wang DR designed the research study, performed the research, analyzed the data, wrote the manuscript, and read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Peking University Third Hospital Department of Obstetrics and Gynaecology.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no interest relationship.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ding-Ran Wang, PhD, Attending Doctor, Department of Obstetrics and Gynaecology, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. ydausidb@163.com
Received: May 24, 2023 Peer-review started: May 24, 2023 First decision: June 12, 2023 Revised: June 15, 2023 Accepted: July 18, 2023 Article in press: July 18, 2023 Published online: August 16, 2023 Processing time: 84 Days and 5.7 Hours
Abstract
BACKGROUND
Endometrial cancer is one of the most commonly diagnosed gynecological cancers worldwide, and early-stage high-risk endometrial cancer has a poor prognosis. Adjuvant treatments after surgery, such as chemotherapy and radiotherapy, have been widely used in clinical practice to improve patient survival. Medroxyprogesterone acetate is a synthetic progestogen that has been reported to have potential anticancer effects in endometrial cancer. However, its efficacy, safety, and long-term prognostic benefits as an adjuvant treatment for endometrial cancer remain controversial. Therefore, this study aimed to observe the efficacy and prognostic impact of adjuvant medroxyprogesterone acetate treatment in patients with early-stage high-risk endometrial cancer and evaluate its safety.
AIM
To observe the efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate and to evaluate its safety.
METHODS
We collected the clinical data of 200 patients with early-stage high-risk endometrial cancer who were admitted to the Department of Obstetrics and Gynecology of our hospital from January 2018 to December 2022. The control group (100 patients) underwent conventional surgical treatment, and the study group (100 patients) was administered adjuvant medroxyprogesterone acetate tablets on top of the control group. The Kaplan-Meier curve analysis and log-rank test were performed to determine the possible factors influencing the 5-year cumulative survival rate in the patients. The Cox regression analysis was performed to identify the factors influencing the survival prognosis of endometrial cancer.
RESULTS
According to the Cox regression analysis, age [hazard ratio (HR) = 4.636, 95% confidence interval (95%CI): 1.411-15.237], pathological type (HR = 6.943, 95%CI: 2.299-20.977), molecular typing (HR = 5.789, 95%CI: 3.305-10.141), and myometrial infiltration (HR = 5.768, 95%CI: 1.898-17.520) were factors influencing the prognosis of patients with early-stage high-risk endometrial cancer.
CONCLUSION
Age, pathological type, molecular typing, and myometrial infiltration were all relevant factors affecting the prognosis of early-stage high-risk endometrial cancer. The potential long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrial cancer is worthy of clinical consideration.
Core Tip: Adjuvant treatment with medroxyprogesterone acetate may have potential long-term prognostic benefits for patients with early-stage high-risk endometrial cancer. Age, pathological type, molecular typing, and myometrial infiltration were identified as relevant factors affecting patient prognosis.
